Although making a definitive diagnosis of liver cancer by hyperactivation of NF-κB and STAT3 is difficult, to date, the efficacy of several developed drugs targeting specific cytokines, such as IL-6, to inhibit NF-κB and STAT3 hyperactivation has been evaluated in phase I and phase II clinical trials in various cancer types [10–12]. Here, NFKB1 is linked to cancer.